Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513

Watchlist Manager
Chengdu Easton Biopharmaceuticals Co Ltd Logo
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Watchlist
Price: 35.07 CNY -3.55% Market Closed
Market Cap: 6.2B CNY
Have any thoughts about
Chengdu Easton Biopharmaceuticals Co Ltd?
Write Note

Chengdu Easton Biopharmaceuticals Co Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Chengdu Easton Biopharmaceuticals Co Ltd
Net Income (Common) Peer Comparison

Comparables:
H
3692
600436
600276
000538
S
688506

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Net Income (Common)
ÂĄ226.6m
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Net Income (Common)
ÂĄ3.3B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Net Income (Common)
ÂĄ3B
CAGR 3-Years
16%
CAGR 5-Years
19%
CAGR 10-Years
22%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Net Income (Common)
ÂĄ5.4B
CAGR 3-Years
-5%
CAGR 5-Years
4%
CAGR 10-Years
15%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Net Income (Common)
ÂĄ4.5B
CAGR 3-Years
-3%
CAGR 5-Years
4%
CAGR 10-Years
6%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Net Income (Common)
-ÂĄ780.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Chengdu Easton Biopharmaceuticals Co Ltd's Net Income (Common)?
Net Income (Common)
226.6m CNY

Based on the financial report for Dec 31, 2023, Chengdu Easton Biopharmaceuticals Co Ltd's Net Income (Common) amounts to 226.6m CNY.

What is Chengdu Easton Biopharmaceuticals Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
11%

Over the last year, the Net Income (Common) growth was -8%. The average annual Net Income (Common) growth rates for Chengdu Easton Biopharmaceuticals Co Ltd have been 8% over the past three years , 11% over the past five years .

Back to Top